News

Reliant began promoting Lescol (fluvastatin sodium) and Lescol XL (fluvastatin sodium extended-release tablets) in January 2001 under a five-year agreement. Under the terms of the extended agreement, Reliant

The UCLA and Veterans Affairs Greater Los Angeles Healthcare System study demonstrated that for arthritis sufferers at high risk for gastrointestinal problems who traditionally may have used a

The study, which included 828 patients with chronic insomnia, augments the findings in Sepracor’s first landmark, six-month study of Lunesta (eszopiclone). This long-term study included a two-week discontinuation

As part of the effort to manufacture GMP grade PBT1 (clioquinol) for clinical trials, Prana found unacceptably high levels of a di-iodo (toxic) form of PBT1. After further

An approvable letter outlines specific questions that have to be resolved before the FDA will approve a product for marketing. The FDA’s questions in this letter relate specifically

Data from a multicenter, phase II trial of a Trisenox (arsenic trioxide) combination regimen, known as MAC (melphalan, Trisenox and vitamin C), were presented by Dr James Berenson,

Development of the compound was discontinued due to what the companies have described as “adverse findings” in on-going animal studies. Although this development program has been discontinued, Merck

Tracleer (bosentan), the first oral dual endothelin receptor antagonist, is approved for the treatment of pulmonary arterial hypertension (PAH) (WHO class III and IV) and made available by

The agreement covers the development of a sustained-release formulation of VasoGenix’s calcitonin gene related peptide (CGRP) using QLT’s Atrigel biodegradable sustained release drug delivery system. Under the terms